.


Exhibit 99.1

Press Release

BioMarin Completes Acquisition of Glyko Biomedical Ltd.

Shareholders and Canadian Regulatory Bodies Approve Transaction -- Glyko
Biomedical Shareholders Become Direct Stockholders of BioMarin

NOVATO, Calif., Aug. 22  /PRNewswire-FirstCall/  -- BioMarin Pharmaceutical Inc.
(Nasdaq and SWX New Market:  BMRN) today  announced  that it has  completed  the
acquisition of all of the outstanding  shares of Glyko Biomedical Ltd. (Toronto:
GBL - News).

BioMarin's  stockholders voted in favor of the transaction at its annual meeting
of  stockholders  held on August 13, 2002, and Glyko  Biomedical's  shareholders
voted in favor of the transaction at a special  meeting of shareholders  held on
August 15, 2002. On August 16, 2002,  the Superior  Court of Justice in Toronto,
Ontario approved the transaction.

Glyko  Biomedical's  principal  asset was  11,367,617  shares of common stock of
BioMarin,  an approximate  21% ownership  interest in BioMarin as of the closing
date. In exchange for all of their shares of Glyko Biomedical,  the shareholders
of Glyko Biomedical received  11,367,617 common shares of BioMarin.  As a result
of the transaction, Glyko Biomedical is now an indirect, wholly owned subsidiary
of BioMarin and the shares of BioMarin  previously held by Glyko Biomedical have
been retired,  with the number of outstanding  shares of BioMarin's common stock
remaining the same.

UBS  Warburg  acted  as  financial  advisor  to  BioMarin  with  regard  to this
transaction.

BioMarin  specializes in the  development and  commercialization  of therapeutic
enzyme   products  to  treat  serious,   life-threatening   diseases  and  other
conditions.

This  press  release  contains  forward-looking  statements  about the  business
prospects of BioMarin Pharmaceutical Inc. and a transaction between BioMarin and
Glyko  Biomedical  Ltd. These  forward-looking  statements are  predictions  and
involve risks and  uncertainties  such that actual results may differ materially
from these  statements.  Results  may differ  materially  and risk  factors  are
detailed in BioMarin's filings with the Securities and Exchange  Commission such
as its proxy  statement  for its  annual  meeting  and Form  10-Q,  10-K and 8-K
reports.  Stockholders are urged not to place undue reliance on  forward-looking
statements,  which  speak  only as of the  date  hereof.  BioMarin  is  under no
obligation,  and  expressly  disclaims  any  obligation,  to update or alter any
forward-looking statement, whether as a result of new information, future events
or otherwise.